Drug intelligence / Profile preview

SNC102

Development stage: Unknown
Lead developer: Simnova Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

SNC102 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), currently under development by Shanghai Simnova Biotech. BCMA is a protein highly and selectively expressed on the surface of plasma cells and is a validated target for the treatment of multiple myeloma. The therapy involves the genetic engineering of a patient's own T cells to express a CAR that specifically binds to BCMA, leading to the targeted destruction of malignant plasma cells upon re-infusion. SNC102 is being investigated in Phase 1 clinical trials for patients with relapsed or refractory multiple myeloma.

Other names: Anti-BCMA CAR T Cell TherapyCART-BCMA

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on SNC102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNC102.

Explore the full profile